OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE: NANO) is pleased to announce the award of a up to NOK 15 million grant from the Research Council of Norway’s User-driven Research-based Innovation programme (in Norwegian; Brukerstyrt innovasjonsarena, BIA) to support the research and development of novel targeted therapeutics for leukemia and non-Hodgkin Lymphoma. The award is based on the promising potential for value creation, both for patients and the society at large, as well as for Nordic Nanovector together with the high quality of research and innovation and the company’s international ambitions.
